ID

34887

Descrizione

A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02456207

collegamento

https://clinicaltrials.gov/show/NCT02456207

Keywords

versioni (1)
  1. 02/02/19 02/02/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

2 febbraio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

Inglese

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. aged from 18 to 75 years;
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
2. having histologically confirmed nhl expressing cd20 antigen;
Descrizione

Non-Hodgkin Lymphoma CD20 expressing

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0024305
UMLS CUI [1,2]
C3888518
3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy;
Descrizione

In complete remission Post Prior Therapy | Complete remission Uncertain Post Prior Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C1514463
UMLS CUI [2,1]
C0677874
UMLS CUI [2,2]
C0087130
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1514463
4. ecog performance status of 0 to 1
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
5. expected survival of at least ≥ 3 months;
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
6. signed an informed consent form which was approved by the institutional review board of the respective medical center .
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment;
Descrizione

rituximab | Anti-CD20 Antibody

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0393022
UMLS CUI [2]
C3891557
2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy;
Descrizione

Cancer treatment Previous | Adrenal Cortex Hormones Previous | Prior Therapy Toxicity Recovery Lacking

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C0205156
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C0600688
UMLS CUI [3,3]
C2004454
UMLS CUI [3,4]
C0332268
3. participating in other clinical trial within 30 days before enrolment;
Descrizione

Study Subject Participation Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
4. with serious hematologic dysfunction (white blood cell count of <3.0×103/ul; absolute neutrophil count of <1.5×103/ ul; platelet count of < 75×103/ul; hemoglobin level of < 8.0 g/dl); hepatic dysfunction (total bilirubin level of > 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of >2.5 × uln; renal dysfunction (serum creatinine level of > 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) > 1.5 × uln (unless on therapeutic coagulation);
Descrizione

Hematologic function Impaired | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Liver Dysfunction | Elevated total bilirubin | Aspartate aminotransferase increased | Alanine aminotransferase increased | Renal dysfunction | Serum creatinine raised | INR raised | Partial thromboplastin time increased | Prolonged activated partial thromboplastin time (aPTT) | Exception Coagulation therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0221099
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0948762
UMLS CUI [4]
C0032181
UMLS CUI [5]
C0518015
UMLS CUI [6]
C0086565
UMLS CUI [7]
C0741494
UMLS CUI [8]
C0151904
UMLS CUI [9]
C0151905
UMLS CUI [10]
C3279454
UMLS CUI [11]
C0700225
UMLS CUI [12]
C0853225
UMLS CUI [13]
C0240671
UMLS CUI [14]
C1837411
UMLS CUI [15,1]
C1705847
UMLS CUI [15,2]
C0441509
5. had received live vaccine within 4 weeks prior to study entry;
Descrizione

Vaccines, Attenuated

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0042211
6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease;
Descrizione

Cancer Other | Central nervous system lymphoma | Lymphoma, AIDS-Related | Opportunistic Infection | Disease Serious Except Malignant Neoplasms

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2]
C0742472
UMLS CUI [3]
C0085090
UMLS CUI [4]
C0029118
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0205404
UMLS CUI [5,3]
C0332300
UMLS CUI [5,4]
C0006826
7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated,
Descrizione

Hepatitis C Antibody Seropositive | HIV Antibody Seropositive | Hepatitis B Surface Antigens Seropositive | Anti-HBc antibody Seropositive | Hbv DNA Test Negative allowed | Hepatitis B surface antigen negative allowed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0166049
UMLS CUI [1,2]
C0521143
UMLS CUI [2,1]
C0019683
UMLS CUI [2,2]
C0521143
UMLS CUI [3,1]
C0019168
UMLS CUI [3,2]
C0521143
UMLS CUI [4,1]
C0948759
UMLS CUI [4,2]
C0521143
UMLS CUI [5,1]
C1256114
UMLS CUI [5,2]
C1513916
UMLS CUI [5,3]
C0683607
UMLS CUI [6,1]
C0919711
UMLS CUI [6,2]
C0683607
8. recent major surgery (within 28 days prior to study entry );
Descrizione

Major surgery

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0679637
9. with a history of allergic reaction or protein product allergy including murine proteins;
Descrizione

Allergic Reaction Proteins | Protein allergy | Hypersensitivity Murine protein

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0033684
UMLS CUI [2]
C1112677
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1699668
10. pregnant or lactating or not accepted birth control methods including male patients.
Descrizione

Pregnancy | Breast Feeding | Gender Contraceptive methods Rejected

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1548437
Ritorna all'inizio della pagina

Similar models

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. aged from 18 to 75 years;
boolean
C0001779 (UMLS CUI [1])
Non-Hodgkin Lymphoma CD20 expressing
Item
2. having histologically confirmed nhl expressing cd20 antigen;
boolean
C0024305 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
In complete remission Post Prior Therapy | Complete remission Uncertain Post Prior Therapy
Item
3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy;
boolean
C0677874 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0677874 (UMLS CUI [2,1])
C0087130 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1514463 (UMLS CUI [2,4])
ECOG performance status
Item
4. ecog performance status of 0 to 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
5. expected survival of at least ≥ 3 months;
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
6. signed an informed consent form which was approved by the institutional review board of the respective medical center .
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
rituximab | Anti-CD20 Antibody
Item
1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment;
boolean
C0393022 (UMLS CUI [1])
C3891557 (UMLS CUI [2])
Cancer treatment Previous | Adrenal Cortex Hormones Previous | Prior Therapy Toxicity Recovery Lacking
Item
2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy;
boolean
C0920425 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C1514463 (UMLS CUI [3,1])
C0600688 (UMLS CUI [3,2])
C2004454 (UMLS CUI [3,3])
C0332268 (UMLS CUI [3,4])
Study Subject Participation Status
Item
3. participating in other clinical trial within 30 days before enrolment;
boolean
C2348568 (UMLS CUI [1])
Hematologic function Impaired | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Liver Dysfunction | Elevated total bilirubin | Aspartate aminotransferase increased | Alanine aminotransferase increased | Renal dysfunction | Serum creatinine raised | INR raised | Partial thromboplastin time increased | Prolonged activated partial thromboplastin time (aPTT) | Exception Coagulation therapy
Item
4. with serious hematologic dysfunction (white blood cell count of <3.0×103/ul; absolute neutrophil count of <1.5×103/ ul; platelet count of < 75×103/ul; hemoglobin level of < 8.0 g/dl); hepatic dysfunction (total bilirubin level of > 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of >2.5 × uln; renal dysfunction (serum creatinine level of > 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) > 1.5 × uln (unless on therapeutic coagulation);
boolean
C0221130 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0023508 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
C0518015 (UMLS CUI [5])
C0086565 (UMLS CUI [6])
C0741494 (UMLS CUI [7])
C0151904 (UMLS CUI [8])
C0151905 (UMLS CUI [9])
C3279454 (UMLS CUI [10])
C0700225 (UMLS CUI [11])
C0853225 (UMLS CUI [12])
C0240671 (UMLS CUI [13])
C1837411 (UMLS CUI [14])
C1705847 (UMLS CUI [15,1])
C0441509 (UMLS CUI [15,2])
Vaccines, Attenuated
Item
5. had received live vaccine within 4 weeks prior to study entry;
boolean
C0042211 (UMLS CUI [1])
Cancer Other | Central nervous system lymphoma | Lymphoma, AIDS-Related | Opportunistic Infection | Disease Serious Except Malignant Neoplasms
Item
6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease;
boolean
C1707251 (UMLS CUI [1])
C0742472 (UMLS CUI [2])
C0085090 (UMLS CUI [3])
C0029118 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C0205404 (UMLS CUI [5,2])
C0332300 (UMLS CUI [5,3])
C0006826 (UMLS CUI [5,4])
Hepatitis C Antibody Seropositive | HIV Antibody Seropositive | Hepatitis B Surface Antigens Seropositive | Anti-HBc antibody Seropositive | Hbv DNA Test Negative allowed | Hepatitis B surface antigen negative allowed
Item
7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated,
boolean
C0166049 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0019683 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019168 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
C0948759 (UMLS CUI [4,1])
C0521143 (UMLS CUI [4,2])
C1256114 (UMLS CUI [5,1])
C1513916 (UMLS CUI [5,2])
C0683607 (UMLS CUI [5,3])
C0919711 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])
Major surgery
Item
8. recent major surgery (within 28 days prior to study entry );
boolean
C0679637 (UMLS CUI [1])
Allergic Reaction Proteins | Protein allergy | Hypersensitivity Murine protein
Item
9. with a history of allergic reaction or protein product allergy including murine proteins;
boolean
C1527304 (UMLS CUI [1,1])
C0033684 (UMLS CUI [1,2])
C1112677 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C1699668 (UMLS CUI [3,2])
Pregnancy | Breast Feeding | Gender Contraceptive methods Rejected
Item
10. pregnant or lactating or not accepted birth control methods including male patients.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1548437 (UMLS CUI [3,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial